

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

H.R.1906, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2000, Title 6, provisions that relate to the FDA budget.


S.1233, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2000, Title 6, provisions that relate to the FDA budget.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Moore, Walter		No
Wagner, Heidi		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 2/14/2000

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 2 of 11

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues


**S. 2536 & H.R. 4461, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2001, Provisions dealing with process patent term extensions
H.R.1907, American Inventors Protection Act of 1999, All provisions as they relate to reform of the patent system.
Patent procedure (no specific legislation).**

17. House(s) of Congress and Federal agencies contacted Check if None
**House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Moore, Walter		No
Wagner, Heidi		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Roche Holding Ltd None

Signature  Date 2/14/2000

Printed Name and Title Walter Moore - Vice President, Government Affairs Page **3** of **11**

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

H.R.2470, Medical Information Protection and Research Enhancement Act of 1999, All provisions as they relate to medical confidentiality.

H.R.10, Financial Services Act of 1999, All provisions as they relate to medical confidentiality.

H.R.306, Genetic Information Nondiscrimination in Health Insurance Act of 1999, All provisions as they relate to genetic information.

S.543, Genetic Information Nondiscrimination in Health Insurance Act of 1999, All provisions as they relate to medical records confidentiality.

S.578, Health Care PIN Act, All provisions as they relate to medical records confidentiality.

H.R.2990, Patients' Bill of Rights, All provisions as they relate to access to clinical trials.

S.1344, Patients' Bill of Rights Plus Act (Public Print), All provisions as they relate to access to clinical trials.

17. House(s) of Congress and Federal agencies contacted Check if None

**Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Moore, Walter		No
Wagner, Heidi		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd None

Signature  Date 2/14/2000

Printed Name and Title Walter Moore - Vice President, Government Affairs Page **4** of **11**

Registrant Name: Genentech, Inc.

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.881, Medical Information Protection Act of 1999, All provisions as they relate to medical records confidentiality.
16	Lobbying Issues	H.R.1957, Medical Information Privacy and Security Act, All provisions as they relate to medical records confidentiality.
16	Lobbying Issues	S.573, Medical Information Privacy and Security Act, All provisions as they relate to medical records confidentiality.
16	Lobbying Issues	

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

S.1480, Seniors Prescription Insurance Coverage Equity (SPICE) Act of 1999, All provisions as they relate to the creation of a Medicare drug benefit.

S.1895, Medicare Preservation and Improvement Act of 1999, All provisions as they relate to the creation of a medicare drug benefit.

H.R.1495, Access to Prescription Medications in Medicare Act of 1999, All provisions as they relate to the creation of a Medicare drug benefit.

H.R.1885, International Prescription Drug Parity Act, All provisions as they relate to the creation of a prescription drug benefit.

S.1191, International Prescription Drug Parity Act, All provisions as they relate to the creation of a prescription drug benefit.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Moore, Walter		No
Wagner, Heidi		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd None

Signature Walter Moore Date 2/14/2000

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 6 of 11

Registrant Name: Genentech, Inc.

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.841, Access to Rx Medications in Medicare Act of 1999, All provisions as they relate to the creation of a Medicare drug benefit.
16	Lobbying Issues	H.R. 664, Prescription Drug Fairness for Seniors Act of 1999, All provisions as they relate to the creation of a Medicare drug benefit.
16	Lobbying Issues	S.731, Prescription Drug Fairness for Seniors Act of 1999, All provisions as they relate to the creation of a Medicare drug benefit.

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SC1 (one per page)

16. Specific Lobbying issues
S.296, Federal Research Investment Act, All provisions as they relate to federal research investment.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Moore, Walter</u>		<u>No</u>
<u>Wagner, Heidi</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Roche Holding Ltd None

Signature  Date 2/14/2000

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 8 of 11

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

H.R.835, To amend the Internal Revenue Code of 1986 to permanently extend the research credit and to adjust the alternative incremental credit rates, All provisions as they relate to the extension of the research and development tax credit.

H.R.760, To amend the Internal Revenue Code of 1986 to permanently extend the research credit, All provisions as they relate to the extension of the research and development tax credit.

S.195, To amend the Internal Revenue Code of 1986 to permanently extend the research credit, All provisions as they relate to the extension of the research and development tax credit.

S.680, To amend the Internal Revenue Code of 1986 to permanently extend the research credit, and for other purposes, All provisions as they relate to the extension of the research and development tax credit.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Moore, Walter</u>		<u>No</u>
<u>Wagner, Heidi</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Roche Holding Ltd None

Signature Walter Moore Date 2/14/2000

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 9 of 11

Registrant Name: Genentech, Inc.

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.1010, To amend the Internal Revenue Code of 1986 to provide for a medical innovation tax credit for clinical testing research expenses attributable to academic medical centers and other qualified... All provisions as they relate to the medical innovation tax credit.
16	Lobbying Issues	H.R.1039, To amend the Internal Revenue Code of 1986 to provide for a medical innovation tax credit for clinical testing research expenses attributable to academic medical centers and other qualified... All provisions as they relate to the medical innovation tax credit.

Registrant Name: Genentech, Inc.

Client Name: Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

GOV, MAN

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client


FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Ownership % in client
Roche Holding Ltd	c/o F. Hoffmann La Roche AG Basel CH-1002 Switzerland		\$0.00	81.00%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client, or affiliated organization

Roche Holding Ltd

Signature  Date 2/14/2009

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 11 of 11